COVID-19 vaccination update from UnitedHealthcare
- steve21713
- Dec 1, 2020
- 2 min read
Preparing for COVID-19 vaccine authorization
COVID-19 vaccines will be an important way to slow the spread of the disease. Helping our customers and members find vaccine information and access vaccines will be our top priority. While there are several COVID-19 vaccines in late-stage trials and one so far that has applied for EUA approval, there are currently no COVID-19 vaccines authorized by the U.S. Food & Drug Administration (FDA). It is also helpful to know that the FDA has a review process to issue emergency use authorizations before vaccines are authorized for use by the general public. While no vaccine is authorized yet, this is likely to happen soon. It is likely the first FDA-authorized COVID-19 vaccines will require two doses several weeks apart. Those that receive a vaccine that requires two doses will need a second dose in the given time frame following the first dose. The CDC website is the best resource for COVID-19 information. When COVID-19 vaccines are authorized by the FDA, members will have $0 cost-share (copayment, coinsurance or deductible), no matter where they get a vaccine, including when two doses are required, as outlined below:
Employer and Individual health plans*: Members will have $0 cost-share at both in- and out-of-network providers through the national public health emergency period. This applies to fully insured and self-funded commercial health plans.
Medicare plans: Members will have $0 cost-share on vaccines at both in- and out-of-network providers through Dec. 31, 2021.
Medicaid: For Medicaid individuals in UnitedHealthcare Community Plans, state variations and regulations may apply during this time. Please review the UnitedHealthcare Community Plan website and your state's site for the latest information. If no state-specific guidance is available, UnitedHealthcare plan guidelines will apply.
To learn more about COVID-19 vaccine developments, potential access and coverage details, click here.
Comments